About the Authors
- Olga Abian
-
* E-mail: oabifra@unizar.es (OA); adrianvc@unizar.es (AVC)
Affiliations Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain, IIS Aragón, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain, Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
- Sonia Vega
-
Affiliation Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain
- Javier Sancho
-
Affiliations Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain, Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza, Spain
- Adrian Velazquez-Campoy
-
* E-mail: oabifra@unizar.es (OA); adrianvc@unizar.es (AVC)
Affiliations Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain, Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza, Spain, Fundación ARAID, Government of Aragon, Zaragoza, Spain
Competing Interests
OA, SV, JS, and AVC have a patent pending on the use of the identified compounds in the treatment of HCV infection. The recently registered patent application is, as follows: EP12382218.1 Allosteric Inhibitors of NS3 Protease from Hepatitis C Virus. This fact does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: OA AVC. Performed the experiments: OA SV. Analyzed the data: OA SV JS AVC. Contributed reagents/materials/analysis tools: OA JS AVC. Wrote the paper: OA SV JS AVC.